The different types and strengths of tirzepatide available in the UK

You've heard there's a starting dose and a maintenance dose, here's why that matters

Picture this: you've read about tirzepatide, you know the clinical trials showed around 20% average body-weight reduction at the highest dose, and you want to know which type you'd actually be taking. The honest answer is that most people begin at 2.5 mg, not because 2.5 mg carries therapeutic weight-loss effect in itself, but because the body needs time to adapt to the way tirzepatide slows gastric emptying and suppresses appetite. Starting lower reduces the likelihood of the nausea and digestive discomfort that tend to hit hardest in the first weeks of treatment. The prescriber's job at this stage is to protect your experience of the medicine, not to rush you to a result.

From 2.5 mg, the prescriber typically moves the dose upward every four weeks (to 5 mg, then 7.5 mg, and so on) only if you're tolerating the current level well. Some people find a middle strength like 7.5 mg or 10 mg suits them long-term, and if you're weighing up whether tirzepatide l is the right format for your stage of treatment, that page covers what that option involves. Others reach the 15 mg maintenance dose and stay there, and those considering whether tirzepatide 30 fits their longer-term plan will find the relevant detail set out there. There is no universal endpoint; the right strength is the one that balances effectiveness with tolerability for you. The tirzepatide overview page explains the mechanism in more detail if you'd like to understand what's happening biologically at each step.

One practical note: if you're planning to start treatment around a bank holiday or a period away from home, timing matters. Dose increases should be supervised, so it's worth coordinating the transition to a new strength for a week when you're in easy contact with your prescriber, not mid-holiday with limited access to support.

What makes tirzepatide different from other injectable treatments, the dual-agonist distinction

The six strength types of tirzepatide share one pharmacological feature that sets the medicine apart from every other weight-loss injection currently licensed in the UK: it activates two receptors rather than one. GLP-1 receptor agonists like semaglutide act on a single pathway; tirzepatide adds GIP receptor activation alongside it. Both pathways influence appetite signalling and blood-sugar regulation, and the combination appears to produce a stronger effect on weight than either pathway alone.

This is worth knowing not as a marketing claim but as a factual reason why the licensed UK strengths of tirzepatide go up to 15 mg when semaglutide's standard injection tops out lower, different medicines with different dose-response curves. A detailed look at what kind of drug tirzepatide is covers the receptor science without oversimplifying it. The NHS also provides a clear patient-level summary at nhs.uk/medicines/tirzepatide, which is a good reference for the side-effect profile of each strength.

The trial evidence for the 15 mg dose (drawn from SURMOUNT-1, involving 2,539 adults with obesity) showed average weight reductions of around 20 to 21% over 72 weeks. Those figures are for the highest strength in a controlled trial setting, not a guarantee for any individual; results vary by starting weight, diet, activity and adherence. What they confirm is that the strength type does matter: the therapeutic effect scales meaningfully as the dose increases through the six levels.

Eligibility (which types of patient the UK licence covers

Tirzepatide is licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above where at least one weight-related condition is present) conditions that include type 2 diabetes, hypertension, high cholesterol and obstructive sleep apnoea, among others. Lower BMI thresholds apply for South Asian, Chinese, other Asian, Middle Eastern, Black African and African-Caribbean backgrounds under UK clinical guidance, reflecting differences in metabolic risk at a given BMI. Licensing thresholds are the floor, not a guarantee of approval: a prescriber assesses the whole clinical picture, including any contraindications or medicines that might interact with treatment.

On the NHS, access is considerably narrower. NICE's appraisal of tirzepatide (TA1026) recommends it for adults with a BMI of 35 or above plus at least one weight-related comorbidity, and the NHS is rolling out access in phases, beginning with those meeting the highest-need criteria. Many people who are eligible by the licensed definition do not yet qualify under NHS criteria, or face a significant wait.

Private treatment through a regulated online pharmacy is the route available in the meantime for people who meet the licensed criteria. If you're considering that route, the Mounjaro treatment page sets out what private prescribing involves, and there's a broader look at your options on the weight-loss treatment overview. Understanding whether Mounjaro and tirzepatide are the same thing is a common early question, they are.

Choosing between strengths, and why that decision isn't yours alone

Reading about tirzepatide types can create the impression that you could choose a starting strength the way you'd choose a supplement dose. The six strengths exist on a clinical ladder, not a menu. The prescriber's role at every stage (including before any dose increase) is to check that treatment is working as expected, that side effects are manageable, and that continuing is appropriate. At nume, a GPhC-registered prescriber reviews every consultation and every repeat order; there are no automated escalations. If you'd like to see how that review process works in practice, the about us page explains our clinical structure.

For most people, the journey through the strength types takes several months. The 2.5 mg pen is the starting point for almost everyone; very few people maintain the lowest dose long-term, and very few need to stay below 5 mg for tolerability reasons. The prescriber will use your response (weight change, side-effect pattern, any new health information) to decide the right next step. That review is also where you'd discuss anything from the common questions patients ask before their next pen arrives.

If you're ready to find out which strength type would be appropriate for you, the right first step is a clinical consultation. Speak to our prescribers via the consultation page, it's free, and a named clinician reviews your answers the same working day.